

Marta Conde (1), Irati Gastesi (2), Lucía de Pablo (1), Sara Villanueva (2), David Aguilera-Alonso (2,3), Ana Esteban (1), Cristina Epalza (4), María López (1), Sara Domínguez (2), Pablo Gómez (1), Álvaro Ballesteros (4), Carlota Pinto (5), Marisa Navarro (6), Carlo Giaquinto (7), Cinta Moraleda (2), Alfredo Tagarro (4) on behalf of EPICO-AEP and ORCHESTRA Working Group

1 Fundación para la Investigación Biomédica e Innovación Hospital Universitario Infanta Sofía y del Henares (FIIB HUIS HHEN), Madrid, 2 Fundación para la Investigación Hospital 12 de Octubre, Madrid, 3 Hospital Universitario Gregorio Marañón, Madrid, 4 Instituto de Investigación 12 de Octubre (imas12), Universidad Complutense de Madrid, RITIP, Paediatric Infectious Diseases, Madrid, 5 Universidad Europea, Investigación, Madrid, 6 Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), CIBERINFEC, RITIP., Paediatric Infectious Diseases, Madrid, 7 University of Padua, Paediatric Infectious Diseases, Padua, Italy.

BACKGROUND

We aimed to describe the prevalence of persistent COVID in hospitalised paediatric population 1 year after admission compared to a control group.

METHODS

Prospective observational study, in 2 hospitals. We included patients aged 0-18 years hospitalised for acute COVID-19 more than 1 year ago and controls, matched by age and sex, hospitalised for causes other than COVID-19, and with no history of COVID-19 at recruitment or during the follow-up. Families were contacted and a standardised survey was conducted. Persistent disease was defined as the presence of symptoms with onset in the first 3 months after admission and with persistence for more than 2 months.

FUNDING

- The ORCHESTRA project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016167.
- The views expressed in this abstract are the sole responsibility of the author and the Commission is not responsible for any use that may be made of the information it contains.
- This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project 20-000995 and co-funded by the European Union*
- Asociación Española de Pediatría


RESULTS

50 cases and 46 controls were analysed, 58.3% male, 36% ≤ 5 years. Families were interviewed a median of 1.89 years (interquartile range; 1.25-2.07) after hospitalisation. The definition of persistent COVID-19/disease was met in 34% of cases vs. 37% of controls ($p=0.767$).

Persistent symptoms were not significantly different in children hospitalized for acute COVID-19 compared to children hospitalized for other reasons

Symptoms persisted ≥ 11 months in 24% (12/50) of cases vs. 13% (6/46) ($p=0.182$), with no differences by age group. The most frequent symptoms at 1 year in cases were fatigue (8%), headache (6%), poor appetite (6%), abdominal pain (6%) and variations in heart rate (6%). In controls, these were abdominal pain (6%) and poor appetite (6%). Readmissions occurred in 11/50 (22%) and 6/46 (13%) ($p=0.267$), respectively. On emotional/behavioural items, 16/50 (32%) of cases reported that their emotional state was worse or much worse than before admission, compared to 16/46 (34.7%).

No risk factors associated with the development of persistent symptoms were found, except the length of hospital admission ($p=0.043$).



CONCLUSIONS

In this study, the prevalence of persistent symptoms was not different in patients with and without COVID-19. 1-year persistence was higher in COVID-19 cases but did not reach significance. Persistence correlated with length of hospitalization